156 related articles for article (PubMed ID: 9822920)
1. Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumours and metastatic carcinoma.
Leong AS; Sormunen RT; Tsui WM; Liew CT
Histopathology; 1998 Oct; 33(4):318-24. PubMed ID: 9822920
[TBL] [Abstract][Full Text] [Related]
2. The utility of hepatocyte paraffin 1 antibody in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma and metastatic carcinoma.
Shiran MS; Isa MR; Sherina MS; Rampal L; Hairuszah I; Sabariah AR
Malays J Pathol; 2006 Dec; 28(2):87-92. PubMed ID: 18376797
[TBL] [Abstract][Full Text] [Related]
3. Utilization of antihepatocyte clone OCH1E5 (Hep Par 1) in histological evaluation of liver tumors.
Amarapurkar AD; Rege JD; Joshi AS; Vaiphei K; Amarapurkar DN
Indian J Pathol Microbiol; 2006 Jul; 49(3):341-4. PubMed ID: 17001880
[TBL] [Abstract][Full Text] [Related]
4. Hep par-1: a novel immunohistochemical marker for differentiating hepatocellular carcinoma from metastatic carcinoma.
Hanif R; Mansoor S
J Coll Physicians Surg Pak; 2014 Mar; 24(3):186-9. PubMed ID: 24613115
[TBL] [Abstract][Full Text] [Related]
5. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma.
Lau SK; Prakash S; Geller SA; Alsabeh R
Hum Pathol; 2002 Dec; 33(12):1175-81. PubMed ID: 12514785
[TBL] [Abstract][Full Text] [Related]
6. Immunoreactivity of Hep Par 1 in hepatic and extrahepatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma.
Kakar S; Muir T; Murphy LM; Lloyd RV; Burgart LJ
Am J Clin Pathol; 2003 Mar; 119(3):361-6. PubMed ID: 12645337
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic utility of the HepPar1 antibody to differentiate hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration samples.
Siddiqui MT; Saboorian MH; Gokaslan ST; Ashfaq R
Cancer; 2002 Feb; 96(1):49-52. PubMed ID: 11836703
[TBL] [Abstract][Full Text] [Related]
8. The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1.
Radwan NA; Ahmed NS
Diagn Pathol; 2012 Oct; 7():149. PubMed ID: 23111165
[TBL] [Abstract][Full Text] [Related]
9. Glypican-3 is useful but not superior to Hep Par 1 in differentiating hepatocellular carcinoma from other liver tumours.
Pour AM; Masir N; Rose IM
Malays J Pathol; 2016 Dec; 38(3):229-233. PubMed ID: 28028292
[TBL] [Abstract][Full Text] [Related]
10. Hep Par 1 in gastric and bowel carcinomas: an immunohistochemical study.
Villari D; Caruso R; Grosso M; Vitarelli E; Righi M; Barresi G
Pathology; 2002 Oct; 34(5):423-6. PubMed ID: 12408340
[TBL] [Abstract][Full Text] [Related]
11. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
Patsenker E; Wilkens L; Banz V; Osterreicher CH; Weimann R; Eisele S; Keogh A; Stroka D; Zimmermann A; Stickel F
J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
[TBL] [Abstract][Full Text] [Related]
12. Cytokeratin profiles and mucin secretion in combined hepatocellular-cholangiocarcinoma. A case report.
Hauben E; Struyf N; Michielsen P; van Marck E
Pathol Res Pract; 1996 May; 192(5):488-91. PubMed ID: 8832755
[TBL] [Abstract][Full Text] [Related]
13. Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections.
Fan Z; van de Rijn M; Montgomery K; Rouse RV
Mod Pathol; 2003 Feb; 16(2):137-44. PubMed ID: 12591966
[TBL] [Abstract][Full Text] [Related]
14. Differential diagnosis of malignant epithelial tumours in the liver: an immunohistochemical study on liver biopsy material.
Al-Muhannadi N; Ansari N; Brahmi U; Satir AA
Ann Hepatol; 2011; 10(4):508-15. PubMed ID: 21911893
[TBL] [Abstract][Full Text] [Related]
15. [Immunohistochemical spectrum in the detection and differentiation of intrahepatic neoplasms].
Cong W; Tan L; Zhang S; Xian Z; Wu W; Pan J; Zhang X
Zhonghua Zhong Liu Za Zhi; 2002 Nov; 24(6):553-6. PubMed ID: 12667323
[TBL] [Abstract][Full Text] [Related]
16. Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver.
Lei JY; Bourne PA; diSant'Agnese PA; Huang J
Am J Clin Pathol; 2006 Apr; 125(4):519-25. PubMed ID: 16627262
[TBL] [Abstract][Full Text] [Related]
17. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein.
Chu PG; Ishizawa S; Wu E; Weiss LM
Am J Surg Pathol; 2002 Aug; 26(8):978-88. PubMed ID: 12170084
[TBL] [Abstract][Full Text] [Related]
18. The expression of cytokeratins 7, 19, and 20 in primary and metastatic carcinomas of the liver.
Maeda T; Kajiyama K; Adachi E; Takenaka K; Sugimachi K; Tsuneyoshi M
Mod Pathol; 1996 Sep; 9(9):901-9. PubMed ID: 8878022
[TBL] [Abstract][Full Text] [Related]
19. The diagnostic utility of the keratin profiles of hepatocellular carcinoma and cholangiocarcinoma.
Johnson DE; Herndier BG; Medeiros LJ; Warnke RA; Rouse RV
Am J Surg Pathol; 1988 Mar; 12(3):187-97. PubMed ID: 2449824
[TBL] [Abstract][Full Text] [Related]
20. Immunohistological evaluation of single small hepatocellular carcinoma with negative staining of monoclonal antibody Hepatocyte Paraffin 1.
Sugiki T; Yamamoto M; Aruga A; Takasaki K; Nakano M
J Surg Oncol; 2004 Nov; 88(2):104-7. PubMed ID: 15499598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
